In 1999, researchers demonstrated in an mdx mouse model of DMD that gentamicin can promote PTC readthrough of the dmd gene to generate a full-length dystrophin protein [30], which led to several clinical trials using an intravenous application of gentamicin in DMD patients [31,32,33]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.